HER2-low breast cancer: the ESMO Expert Consensus Statements

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

#ESMO21 Expert Video Report on HER2-positive early breast cancerПодробнее

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast CancerПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

#ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancersПодробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast CancerПодробнее

ESO-ESMO-ABC guidelines in metastatic breast cancerПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Questions remaining in the field of HER2-low breast cancerПодробнее

Remaining questions surrounding HER2-low breast cancer – how low can you go?Подробнее

Treatement of HER2 Low Breast CancerПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022Подробнее